ReviewCancer gene therapy2017
Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.
Review in Cancer gene therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Review
- The Evolving Role of Induced Pluripotent Stem Cells and Cerebral Organoids in Treating and Modeling Neurosurgical Diseases.World neurosurgery · 2021Review
- GD2 CAR T cells against human glioblastoma.NPJ precision oncology · 2021Article
- Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs.Cancer immunology research · 2021Article
- The Association of Human Herpesviruses with Malignant Brain Tumor Pathology and Therapy: Two Sides of a Coin.International journal of molecular sciences · 2021Review
- Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Review
- Preparation and characterisation of silica-based nanoparticles for cisplatin release on cancer brain cells.IET nanobiotechnology · 2020Article
- T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.Journal for immunotherapy of cancer · 2019Article
- Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.Neuro-oncology · 2018Article
- Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Novel Immunotherapeutics for the Treatment of Glioblastoma: The Last Decade of Research.Cureus · 2018Review
- Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy.Neurologia medico-chirurgica · 2017Review
- Single vs. combination immunotherapeutic strategies for glioma.Expert opinion on biological therapy · 2017Review
- Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials.F1000Research · 2017Review
- Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.Current pharmaceutical design · 2017Review
- Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is by far the most common and the most aggressive of all the primary brain malignancies. No curative therapy exists, and median life expectancy hovers at around 1 year after diagnosis, with a minute fraction surviving beyond 5 years. The difficulty in treating GBM lies in the cancer's protected niche within the blood-brain barrier and the heterogeneity of the cancer cells, which possess varying degrees of susceptibility to various common modalities of treatment. Over time, it is the tumor heterogeneity of GBM and the ability of the cancer stem cells to evolve in response treatment that renders the cancer refractory to conventional treatment. Therefore, research has increasingly focused on treatment that incorporates knowledge of GBM molecular biology to therapeutic strategies. One type of therapy that shows great promise is the area of T-cell immunotherapy to target GBM-specific tumor antigens. One attractive strategy is to use T cells that have undergone genetic modification to express a chimeric antigen receptor capable of interacting with tumor antigens. In this article, we will review chimeric antigen receptor T-cell therapy, their advantages, drawbacks, challenges facing their use and how those challenges may be overcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.